141 related articles for article (PubMed ID: 17560019)
1. Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment.
Bergan L; Gross JA; Nevin B; Urban N; Scholler N
Cancer Lett; 2007 Oct; 255(2):263-74. PubMed ID: 17560019
[TBL] [Abstract][Full Text] [Related]
2. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.
Scholler N; Garvik B; Hayden-Ledbetter M; Kline T; Urban N
Cancer Lett; 2007 Mar; 247(1):130-6. PubMed ID: 16677756
[TBL] [Abstract][Full Text] [Related]
3. A binding domain on mesothelin for CA125/MUC16.
Kaneko O; Gong L; Zhang J; Hansen JK; Hassan R; Lee B; Ho M
J Biol Chem; 2009 Feb; 284(6):3739-49. PubMed ID: 19075018
[TBL] [Abstract][Full Text] [Related]
4. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
5. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.
Rump A; Morikawa Y; Tanaka M; Minami S; Umesaki N; Takeuchi M; Miyajima A
J Biol Chem; 2004 Mar; 279(10):9190-8. PubMed ID: 14676194
[TBL] [Abstract][Full Text] [Related]
6. A novel high-affinity human monoclonal antibody to mesothelin.
Ho M; Feng M; Fisher RJ; Rader C; Pastan I
Int J Cancer; 2011 May; 128(9):2020-30. PubMed ID: 20635390
[TBL] [Abstract][Full Text] [Related]
7. Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.
Scholler N; Lowe KA; Bergan LA; Kampani AV; Ng V; Forrest RM; Thorpe JD; Gross JA; Garvik BM; Drapkin R; Anderson GL; Urban N
Clin Cancer Res; 2008 May; 14(9):2647-55. PubMed ID: 18451228
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Li Q; Verschraegen CF; Mendoza J; Hassan R
Anticancer Res; 2004; 24(3a):1327-35. PubMed ID: 15274292
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.
Coelho R; Marcos-Silva L; Ricardo S; Ponte F; Costa A; Lopes JM; David L
Expert Rev Anticancer Ther; 2018 Feb; 18(2):177-186. PubMed ID: 29241375
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Hassan R; Ebel W; Routhier EL; Patel R; Kline JB; Zhang J; Chao Q; Jacob S; Turchin H; Gibbs L; Phillips MD; Mudali S; Iacobuzio-Donahue C; Jaffee EM; Moreno M; Pastan I; Sass PM; Nicolaides NC; Grasso L
Cancer Immun; 2007 Dec; 7():20. PubMed ID: 18088084
[TBL] [Abstract][Full Text] [Related]
11. Molecular Imaging of Mesothelin-Expressing Ovarian Cancer with a Human and Mouse Cross-Reactive Nanobody.
Prantner AM; Yin C; Kamat K; Sharma K; Lowenthal AC; Madrid PB; Scholler N
Mol Pharm; 2018 Apr; 15(4):1403-1411. PubMed ID: 29462558
[TBL] [Abstract][Full Text] [Related]
12. Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway.
Huo Q; Xu C; Shao Y; Yu Q; Huang L; Liu Y; Bao H
Int J Biol Sci; 2021; 17(2):574-588. PubMed ID: 33613114
[No Abstract] [Full Text] [Related]
13. Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?
Creaney J; Dick IM; Dare H; Demelker Y; Nowak AK; Musk AW; Robinson BW
Lung Cancer; 2013 Apr; 80(1):39-44. PubMed ID: 23357461
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma.
Einama T; Kamachi H; Nishihara H; Homma S; Kanno H; Takahashi K; Sasaki A; Tahara M; Okada K; Muraoka S; Kamiyama T; Matsuno Y; Ozaki M; Todo S
Pancreas; 2011 Nov; 40(8):1276-82. PubMed ID: 21775916
[TBL] [Abstract][Full Text] [Related]
15. Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells.
Steinbach D; Onda M; Voigt A; Dawczynski K; Wittig S; Hassan R; Gruhn B; Pastan I
Eur J Haematol; 2007 Oct; 79(4):281-6. PubMed ID: 17803679
[TBL] [Abstract][Full Text] [Related]
16. MUC16 expression and risk of adenocarcinoma metastases to peritoneum, pleura, leptomeninges, and brain.
Johnson MD; Vito F; Xu H
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):250-3. PubMed ID: 20090516
[TBL] [Abstract][Full Text] [Related]
17. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
Creaney J; van Bruggen I; Hof M; Segal A; Musk AW; de Klerk N; Horick N; Skates SJ; Robinson BW
Chest; 2007 Oct; 132(4):1239-46. PubMed ID: 17646232
[TBL] [Abstract][Full Text] [Related]
18. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor.
Huang CY; Cheng WF; Lee CN; Su YN; Chien SC; Tzeng YL; Hsieh CY; Chen CA
Anticancer Res; 2006; 26(6C):4721-8. PubMed ID: 17214332
[TBL] [Abstract][Full Text] [Related]
19. Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer.
Aktas B; Kasimir-Bauer S; Wimberger P; Kimmig R; Heubner M
Anticancer Res; 2013 Jan; 33(1):329-36. PubMed ID: 23267165
[TBL] [Abstract][Full Text] [Related]
20. Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding.
Sirois AR; Deny DA; Baierl SR; George KS; Moore SJ
PLoS One; 2018; 13(5):e0197029. PubMed ID: 29738555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]